Introduction
Enhanced External Counterpulsation (EECP) is a non-invasive mode of treatment which is given on outpatient basis. This method is used to improve myocardial perfusion and cardiac output, thereby reducing symptoms of angina and heart failure 1 EECP is used to stabilize the coronary circulation in patients with severe coronary artery disease when maximal medical therapy and/or invasive procedures have proven inadequate or exhausted 1 . Improved technology in percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG) has made it possible to successfully treat patients with chronic angina pectoris. However, a large number of patients remain symptomatic in spite of PTCA or CABG, continue to be ineffective or associated with an unacceptable risk of complications. There is an increasingly large population of patients who have persistent residual anginal symptoms and they remain severely restricted physically 2 Following bypass surgery, only 75% of patients are symptom free from ischemic events for 5 years or more, and only 50% remain so after 10 years or more 3 EECP has been shown to be effective in these group of patient 4, 5 Complete resolution of ischemic perfusion defects was achieved in 67%, partial reperfusion with decrease in size of defects was noted in 11%, and no change was seen in 22% of patients 5 
History of Counterpulsation
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The goals of EECP: 14 
Increased Higher Augmented Diastolic Pressure
This increase diastole pressure thus increase coronary blood flow and recruit dormant collateral vessels. Oxygen supply to ischemic myocardium is increased.
Lowered Assisted Systolic Pressure
This lowered systolic pressure decreases the oxygen demand of the heart.
Lowered End-diastolic Pressure
This lowered pressure at the end of diastole aids in increasing coronary blood flow and decreasing resistance before systole. Oxygen supply is increased and demand is decreased.
Increased Venous Return
The cuffs squeezing the lower extremities, increases blood return to the right side of the heart. This increased blood return can increase preload, increase the stretch on the myocardial fibers, and subsequently increase cardiac output. 
For Whom EECP is?
EECP therapy is indicated for patients with coronary artery disease who either cannot undergo angioplasty or bypass surgery, or have persistent anginal symptoms following angioplasty or bypass surgery. EECP for use in stable and unstable angina, acute myocardial infarction (MI), cardiogenic shock, and heart failure (HF) 10, 11 The EECP therapy was observed to be a safe and effective treatment of angina in patients with severe left ventricular dysfunction (LVD) who were not considered good candidates for revascularization by coronary artery bypass graft or percutaneous coronary intervention 15 pressure. The diastolic augmentation increases coronary perfusion pressure and provides afterload reduction and increase venous return with a subsequent increase in cardiac output 12 The degree of hemodynamic effect is monitored by the ratio of systolic to diastolic pressures, which is recorded by finger plethysmography. A usual course of EECP treatment consists of minimum 35 one-hour sessions.
Levenson et al. postulated that an increase in cyclic guanosine monophosphate (cGMP) acutely after EECP therapy might in part be responsible for the improved peripheral arterial function 13 Cyclic guanosine monophosphate regulates vascular smooth muscle tone, which may improve arterial function. Fifty-five subjects were randomized into 2 groups to receive either sham (control) or active EECP therapy for the duration of 1 hour . Plasma and platelet cGMP were measured immediately before and after EECP therapy by radioimmunoassay 13 One hour of EECP therapy increased cGMP plasma concentration by 52% and platelet content by 19% 13 This theory of endothelial stabilization has attracted the most attention in the recent past as one of the primary mechanisms of action, with more clinical trials needed to further understand it completely 13 
